High CDC20 expression is associated with poor prognosis in oral squamous cell carcinoma

Journal of Oral Pathology and Medicine

Volumn 43, Issue 3, 2014, Pages 225-231

  Moura, Inês M B ^a   Delgado, Maria L ^a   Silva, Patrícia M A ^a   Lopes, Carlos A ^b   do Amaral, José B ^c   Monteiro, Luís S ^a   Bousbaa, Hassan ^a  

^a UNIVERSITY INSTITUTE OF HEALTH SCIENCES IUCS   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

^c HOSPITAL DE SANTO ANTÓNIO   (Portugal)

Author keywords

CDC20 expression; Oral cavity cancer; Prognostic marker; Spindle assembly checkpoint

Indexed keywords

CELL CYCLE PROTEIN 20; ANAPHASE PROMOTING COMPLEX; CCNB1 PROTEIN, HUMAN; CDC20 PROTEIN, HUMAN; CYCLIN B1; PITUITARY TUMOR-TRANSFORMING PROTEIN 1, HUMAN; SECURIN; TUMOR MARKER;

ADULT; ARTICLE; CANCER SPECIFIC SURVIVAL; CLINICAL FEATURE; FEMALE; HIGH RISK PATIENT; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MOUTH SQUAMOUS CELL CARCINOMA; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STATISTICAL ANALYSIS; TISSUE MICROARRAY; CANCER GRADING; CANCER STAGING; CHEMISTRY; DISEASE FREE SURVIVAL; FOLLOW UP; LYMPH NODE METASTASIS; M PHASE CELL CYCLE CHECKPOINT; METABOLISM; MICROARRAY ANALYSIS; MIDDLE AGED; MOUTH TUMOR; PATHOLOGY; PHYSIOLOGY; RETROSPECTIVE STUDY; SECONDARY; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE; TUMOR INVASION; TUMOR RECURRENCE;

ANAPHASE-PROMOTING COMPLEX-CYCLOSOME; CARCINOMA, SQUAMOUS CELL; CDC20 PROTEINS; CYCLIN B1; DISEASE-FREE SURVIVAL; FEMALE; FOLLOW-UP STUDIES; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; M PHASE CELL CYCLE CHECKPOINTS; MALE; MICROARRAY ANALYSIS; MIDDLE AGED; MOUTH NEOPLASMS; NEOPLASM GRADING; NEOPLASM INVASIVENESS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SECURIN; SURVIVAL RATE; TUMOR MARKERS, BIOLOGICAL;

EID: 84896317021     PISSN: 09042512     EISSN: 16000714     Source Type: Journal    
DOI: 10.1111/jop.12115     Document Type: Article

References (24)

1. Tanaka T, Tanaka M. Oral carcinogenesis and oral cancer chemoprevention: a review. Patholog Res Int 2011; 2011: 431246.
2. Warnakulasuriya S. Global epidemiology of oral and oropharyngeal cancer. Oral Oncol 2009; 45: 309-16.
3. Tsantoulis PK, Kastrinakis NG, Tourvas AD, Laskaris G, Gorgoulis VG. Advances in the biology of oral cancer. Oral Oncol 2007; 43: 523-34.
4. Musacchio A, Salmon ED. The spindle-assembly checkpoint in space and time. Nat Rev Mol Cell Biol 2007; 8: 379-93.
5. Kops GJ, Weaver BA, Cleveland DW. On the road to cancer: aneuploidy and the mitotic checkpoint. Nat Rev Cancer 2005; 5: 773-85.
6. Silva P, Barbosa J, Nascimento AV, Faria J, Reis R, Bousbaa H. Monitoring the fidelity of mitotic chromosome segregation by the spindle assembly checkpoint. Cell Prolif 2011; 44: 391-400.
7. Sudakin V, Chan GK, Yen TJ. Checkpoint inhibition of the APC/C in HeLa cells is mediated by a complex of BUBR1, BUB3, CDC20, and MAD2. J Cell Biol 2001; 154: 925-36.
8. Mondal G, Sengupta S, Panda CK, Gollin SM, Saunders WS, Roychoudhury S. Overexpression of Cdc20 leads to impairment of the spindle assembly checkpoint and aneuploidization in oral cancer. Carcinogenesis 2007; 28: 81-92.
9. Kim JM, Sohn HY, Yoon SY, et al. Identification of gastric cancer-related genes using a cDNA microarray containing novel expressed sequence tags expressed in gastric cancer cells. Clin Cancer Res 2005; 11: 473-82.
10. Chang DZ, Ma Y, Ji B, et al. Increased CDC20 expression is associated with pancreatic ductal adenocarcinoma differentiation and progression. J Hematol Oncol 2012; 5: 15.
11. Kato T, Daigo Y, Aragaki M, Ishikawa K, Sato M, Kaji M. Overexpression of CDC20 predicts poor prognosis in primary non-small cell lung cancer patients. J Surg Oncol 2012; 106: 423-30.
12. Marucci G, Morandi L, Magrini E, et al. Gene expression profiling in glioblastoma and immunohistochemical evaluation of IGFBP-2 and CDC20. Virchows Arch 2008; 453: 599-609.
13. Edge SB, Byrd DR, Compton CC, Fritz AG, Greene FL, Trotti A, eds. American joint committee on cancer: cancer staging manual, 7th edn. New York, NY: Springer, 2010.
14. Barnes L, Eveson JW, Reichart P, Sidransky D, eds. World health organization classification of tumours: pathology and genetics of head and neck tumours. Lyon: IARC Press, 2005.
15. Monteiro LS, Diniz-Freitas M, Garcia-Caballero T, Forteza J, Fraga M. EGFR and Ki-67 expression in oral squamous cell carcinoma using tissue microarray technology. J Oral Pathol Med 2010; 39: 571-8.
16. Schmidt M, Medema RH. Exploiting the compromised spindle assembly checkpoint function of tumor cells: dawn on the horizon? Cell Cycle 2006; 5: 159-63.
17. Zaravinos A, Lambrou GI, Boulalas I, Delakas D, Spandidos DA. Identification of common differentially expressed genes in urinary bladder cancer. PLoS ONE 2011; 6: e18135.
18. Rajkumar T, Sabitha K, Vijayalakshmi N, et al. Identification and validation of genes involved in cervical tumourigenesis. BMC Cancer 2011; 11: 80.
19. Ouellet V, Guyot MC, le Page C, et al. Tissue array analysis of expression microarray candidates identifies markers associated with tumor grade and outcome in serous epithelial ovarian cancer. Int J Cancer 2006; 119: 599-607.
20. Huang HC, Shi J, Orth JD, Mitchison TJ. Evidence that mitotic exit is a better cancer therapeutic target than spindle assembly. Cancer Cell 2009; 16: 347-58.
21. Wang LG, Liu XM, Kreis W, Budman DR. The effect of antimicrotubule agents on signal transduction pathways of apoptosis: a review. Cancer Chemother Pharmacol 1999; 44: 355-61.
22. Weaver BA, Cleveland DW. Decoding the links between mitosis, cancer, and chemotherapy: the mitotic checkpoint, adaptation, and cell death. Cancer Cell 2005; 8: 7-12.
23. Gascoigne KE, Taylor SS. Cancer cells display profound intra- and interline variation following prolonged exposure to antimitotic drugs. Cancer Cell 2008; 14: 111-22.
24. Rieder CL, Maiato H. Stuck in division or passing through: what happens when cells cannot satisfy the spindle assembly checkpoint. Dev Cell 2004; 7: 637-51.